Diagnostic antibodies and antigens for metabolic diseases testing: 25-OH-(VD3+VD2), PINP, N-MID OC, β-CTx, 25-OH-VD, 25-OH-VD-3, SAHH, CBL, CBS, LP-PLA2, RBP4

Metabolism is the process of making energy from the food. metabolic disease, any of the diseases or disorders that disrupt normal metabolism, the process of converting food to energy on a cellular level. Thousands of enzymes participating in numerous interdependent metabolic pathways carry out this process. Metabolic diseases affect the ability of the cell to perform critical biochemical reactions that involve the processing or transport of proteins (amino acids), carbohydrates (sugars and starches), or lipids (fatty acids). The consequences of metabolic disorder may be severe; intellectual disability, seizures, decreased muscle tone, organ failure, blindness, and deafness may occur, depending on which enzyme is dysfunctional. Biomarker such as -25 hydroxyvitamin D, procollagen type I N-terminal propeptide (PINP), β-isomerized C-terminal telopeptides, 25-hydroxy (OH) Vitamin, S-adenosylhomocysteine (AdoHcy) hydrolase, cystathionine-β-synthase enzyme, Phospholipase A2, Retinol binding protein 4 and so on are suitable for monitoring metabolic disease. Detecting the quantity of these marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.

Classification: 25-OH-(VD3+VD2) PINP N-MID OC β-CTx 25-OH-VD 25-OH-VD-3 SAHH CBL CBS LP-PLA2 RBP4

25 hydroxyvitamin D (25-OH-(VD3+VD2))

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-SMT-25-OH-VD3/2	Human	25 hydroxyvitamin D (25-OH-(VD3+VD2))	bone fracture, coronary heart disease, cancer, and all-cause mortality	GMP-SMT-25-OH-VD3/2-Ag01: BSA-25 hydroxyvitamin D (25-OH-(VD3+VD2)) GMP-SMT-25-OH-VD3/2-Ag02: OVA-25 hydroxyvitamin D (25-OH-(VD3+VD2))	Competitive immunoassay-validated hapten-carrier conjugates [BSA-&OVA-25 hydroxyvitamin D (25-OH-(VD3+VD2))], 25 hydroxyvitamin D (25-OH-(VD3+VD2)) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in 25-OH-(VD3+VD2) level test of Metabolic diseases (bone fracture, coronary heart disease, cancer, and all-cause mortality) and related syndrome evaluation.	GMP-SMT-25-OH-VD3/2-Ab01: Anti-25 hydroxyvitamin D (25-OH-(VD3+VD2)) mouse monoclonal antibody(mAb)	Human 25 hydroxyvitamin D (25-OH-(VD3+VD2)) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in 25-OH-(VD3+VD2) level test of Metabolic diseases (bone fracture, coronary heart disease, cancer, and all-cause mortality) and related syndrome evaluation.

procollagen type I N-terminal propeptide (PINP)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-h-PINP	Human	procollagen type I N-terminal propeptide (PINP)	osteoporosis therapy	GMP-h-PINP-Ag01: Recombinant human PINP Protein	procollagen type I N-terminal propeptide (PINP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in PINP level test of Metabolic diseases(osteoporosis therapy) and related syndrome evaluation.	GMP-h-PINP-Ab01; GMP-h-PINP-Ab02: Anti-human PINP mouse monoclonal antibody(mAb)	Human procollagen type I N-terminal propeptide (PINP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other procollagen type I N-terminal propeptide (PINP) antibodies in PINP level test of Metabolic diseases (osteoporosis therapy) and related syndrome evaluation.

N-terminal midfragment of Osteocalcin (N-MID OC)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-h-N-MID-OC	Human	N-terminal midfragment of Osteocalcin (N-MID OC)	osteoporosis	GMP-h-N-MID-OC-Ag01: Recombinant Human N-MID OC Protein	N-terminal midfragment of Osteocalcin (N-MID OC) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in N-MID OC level test of Metabolic diseases (osteoporosis) and related syndrome evaluation	GMP-h-N-MID-OC-Ab01; GMP-h-N-MID-OC-Ab02: Anti-Human N-MID OC mouse monoclonal antibody (mAb)	Human N-terminal midfragment of Osteocalcin (N-MID OC) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other N-terminal midfragment of Osteocalcin (N-MID OC) antibodies in N-MID OC level test of Metabolic diseases (osteoporosis) and related syndrome evaluation.

β-isomerized C-terminal telopeptides (β-CTx)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-h-β-CTx	Human	β-isomerized C-terminal telopeptides (β-CTx)	osteoporosis	GMP-h-β-CTx-Ag01: Recombinant human β-CTx Protein	β-isomerized C-terminal telopeptides (β-CTx) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in β-CTx level test of Metabolic diseases(osteoporosis) and related syndrome evaluation.	GMP-h-β-CTx-Ab01; GMP-h-β-CTx-Ab02: Anti-human β-CTx mouse monoclonal antibody(mAb)	Human β-isomerized C-terminal telopeptides (β-CTx) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other β-isomerized C-terminal telopeptides (β-CTx) antibodies in β-CTx level test of Metabolic diseases (osteoporosis) and related syndrome evaluation.

25-hydroxy (OH) Vitamin (25-OH-VD)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-SMT-25-OH-VD	Human	25-hydroxy (OH) Vitamin (25-OH-VD)	osteoporosis and rickets	GMP-SMT-25-OH-VD-Ag01: BSA-25-hydroxy (OH) Vitamin (25-OH-VD) GMP-SMT-25-OH-VD-Ag02: OVA-25-hydroxy (OH) Vitamin (25-OH-VD)	Competitive immunoassay-validated hapten-carrier conjugates [BSA-&OVA-25-hydroxy (OH) Vitamin (25-OH-VD)], 25-hydroxy (OH) Vitamin (25-OH-VD) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in 25-OH-VD level test of Metabolic diseases (osteoporosis and rickets) and related syndrome evaluation.	GMP-SMT-25-OH-VD-Ab01: Anti-25-hydroxy (OH) Vitamin (25-OH-VD) mouse monoclonal antibody(mAb)	Human 25-hydroxy (OH) Vitamin (25-OH-VD) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in 25-OH-VD level test of Metabolic diseases (osteoporosis and rickets) and related syndrome evaluation.

25-hydroxy (OH) Vitamin (25-OH-VD)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-SMT-25-OH-VD-3	Human	25-hydroxy (OH) Vitamin D3 (25-OH-VD-3)	osteoporosis and rickets	GMP-SMT-25-OH-VD-3-Ag01: BSA-25-hydroxy (OH) Vitamin D3 (25-OH-VD) GMP-SMT-25-OH-VD-3-Ag02: OVA-25-hydroxy (OH) Vitamin D3 (25-OH-VD-3)	Competitive immunoassay-validated hapten-carrier conjugates [BSA-&OVA-25-hydroxy (OH) Vitamin D3 (25-OH-VD-3)], 25-hydroxy (OH) Vitamin D3 (25-OH-VD-3) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in 25-OH-VD-3 level test of Metabolic diseases (osteoporosis and rickets) and related syndrome evaluation.	GMP-SMT-25-OH-VD-3-Ab01; GMP-SMT-25-OH-VD-3-Ab02: Anti-25-hydroxy (OH) Vitamin D3 (25-OH-VD-3) mouse monoclonal antibody(mAb)	Human 25-hydroxy (OH) Vitamin D3 (25-OH-VD-3) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in 25-OH-VD-3 level test of Metabolic diseases (osteoporosis and rickets) and related syndrome evaluation.

S-adenosylhomocysteine (AdoHcy) hydrolase (SAHH)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-h-SAHH	Human	S-adenosylhomocysteine (AdoHcy) hydrolase (SAHH)	S-adenosylhomocysteine (AdoHcy) hydrolase deficiency	GMP-h-SAHH-Ag01: Recombinant human SAHH Protein	S-adenosylhomocysteine (AdoHcy) hydrolase (SAHH) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in SAHH level test of Metabolic diseases(S-adenosylhomocysteine (AdoHcy) hydrolase deficiency) and related syndrome evaluation.	GMP-h-SAHH-Ab01; GMP-h-SAHH-Ab02: Anti-human SAHH mouse monoclonal antibody(mAb)	Human S-adenosylhomocysteine (AdoHcy) hydrolase (SAHH) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other S-adenosylhomocysteine (AdoHcy) hydrolase (SAHH) antibodies in SAHH level test of Metabolic diseases (S-adenosylhomocysteine (AdoHcy) hydrolase deficiency) and related syndrome evaluation.

cystathionine-β-synthase enzyme (CBL)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-h-CBL	Human	cystathionine-β-synthase enzyme (CBL)	ectopia lentis, learning difficulties and skeletal abnormalities	GMP-h-CBL-Ag01: Recombinant human CBL Protein	cystathionine-β-synthase enzyme (CBL) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in CBL level test of Metabolic diseases(ectopia lentis, learning difficulties and skeletal abnormalities) and related syndrome evaluation.	GMP-h-CBL-Ab01; GMP-h-CBL-Ab02: Anti-human CBL mouse monoclonal antibody(mAb)	Human cystathionine-β-synthase enzyme (CBL) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other cystathionine-β-synthase enzyme (CBL) antibodies in CBL level test of Metabolic diseases (ectopia lentis, learning difficulties and skeletal abnormalities) and related syndrome evaluation.

cystathionine-β-synthase enzyme (CBS)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-h-CBS	Human	cystathionine-β-synthase enzyme (CBS)	ectopia lentis, learning difficulties and skeletal abnormalities	GMP-h-CBS-Ag01: Recombinant human CBS Protein	cystathionine-β-synthase enzyme (CBS) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in CBS level test of Metabolic diseases(ectopia lentis, learning difficulties and skeletal abnormalities) and related syndrome evaluation.	GMP-h-CBS-Ab01; GMP-h-CBS-Ab02: Anti-human CBS mouse monoclonal antibody(mAb)	Human cystathionine-β-synthase enzyme (CBS) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other cystathionine-β-synthase enzyme (CBS) antibodies in CBS level test of Metabolic diseases (ectopia lentis, learning difficulties and skeletal abnormalities) and related syndrome evaluation.

Phospholipase A2 (LP-PLA2)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-SMT-LP-PLA2	Human	Phospholipase A2 (LP-PLA2)	atherosclerosis, hyperlipidemia, obesity, and diabetes	GMP-SMT-LP-PLA2-Ag01: BSA-Phospholipase A2 (LP-PLA2)	Competitive immunoassay-validated hapten-carrier conjugates [BSA-Phospholipase A2 (LP-PLA2)], Phospholipase A2 (LP-PLA2) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in LP-PLA2 level test of Metabolic diseases (atherosclerosis, hyperlipidemia, obesity, and diabetes) and related syndrome evaluation.	GMP-SMT-LP-PLA2-Ab01; GMP-SMT-LP-PLA2-Ab02: Anti-Phospholipase A2 (LP-PLA2) mouse monoclonal antibody(mAb)	Human Phospholipase A2 (LP-PLA2) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in LP-PLA2 level test of Metabolic diseases (atherosclerosis, hyperlipidemia, obesity, and diabetes) and related syndrome evaluation.

Retinol binding protein 4 (RBP4)

Cat No.	Species	Biomarker	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-SMT-RBP4	Human	Retinol binding protein 4 (RBP4)	obesity, type 2 diabetes, metabolic syndrome, and cardiovascular diseases	GMP-SMT-RBP4-Ag01: BSA-Retinol binding protein 4 (RBP4)	Competitive immunoassay-validated hapten-carrier conjugates [BSA-Retinol binding protein 4 (RBP4)], Retinol binding protein 4 (RBP4) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in RBP4 level test of Metabolic diseases (obesity, type 2 diabetes, metabolic syndrome, and cardiovascular diseases) and related syndrome evaluation.	GMP-SMT-RBP4-Ab01; GMP-SMT-RBP4-Ab02: Anti-Retinol binding protein 4 (RBP4) mouse monoclonal antibody(mAb)	Human Retinol binding protein 4 (RBP4) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in RBP4 level test of Metabolic diseases (obesity, type 2 diabetes, metabolic syndrome, and cardiovascular diseases) and related syndrome evaluation.